<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02688036</url>
  </required_header>
  <id_info>
    <org_study_id>CH-L-045/2</org_study_id>
    <nct_id>NCT02688036</nct_id>
  </id_info>
  <brief_title>Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC</brief_title>
  <official_title>Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether hypofractionated concurrent
      chemo-radiotherapy has the same efficiency as conventionally fractionated concurrent
      chemo-radiotherapy in Limited Disease Small Cell Lung Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with
      concurrent chemotherapy will be used in experimental arm. While 60Gy/30F of radiotherapy with
      concurrent chemotherapy will be used in the control arm. Both survival and toxicity of the
      two arms will be observed and compared.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local-regional failure (Incidence of tumor recurrence in local or regional area)</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of tumor recurrence in local or regional area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity (Incidence of radiotherapy and chemotherapy induced toxicities assessed by CTCAE v 4.0)</measure>
    <time_frame>2 year</time_frame>
    <description>Incidence of radiotherapy and chemotherapy induced toxicities assessed by CTCAE v 4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">860</enrollment>
  <condition>Carcinoma, Small Cell</condition>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>hypofractionated CRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hypofractionated concurrent chemoradiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventionally fractionated CRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventionally fractionated concurrent chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated concurrent chemoradiotherapy</intervention_name>
    <description>For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm.</description>
    <arm_group_label>hypofractionated CRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>conventionally fractionated concurrent chemoradiotherapy</intervention_name>
    <description>For patients with Limited Disease Small Cell Lung Cancer, 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm.</description>
    <arm_group_label>conventionally fractionated CRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18~70 years old, ECOG 0-2

          -  patients with histologically or cytologically proved small cell lung cancer

          -  Limited disease (LD), was characterized by tumors confined to one hemithorax. It may
             include ipsilateral hilar, both mediastinum and both supraclavicular nodes. Metastatic
             lymph nodes were defined as lymph nodes with short diameter of more than 1cm or FDG
             uptake in PET. The thickness of pleural effusion was less than 1cm unless malignant
             pleural effusion was cytologically proved. In a word, stage I-IIIB excluding the
             patients with lung metastases should be defined as LD according to AJCC cancer staging
             7th edition.

          -  No progression after 2 cycles of chemotherapy with EP.

          -  No prior history of anti-tumor treatment.

          -  No severe internal diseases and no organ dysfunction

          -  Written informed consent provided and

        Exclusion Criteria:

          -  Malignant tumors of other sites. Non melanoma skin cancer and Cervical carcinoma in
             situ were not included if curable.

          -  Active heart disease or acute myocardial infarction happen in six months.

          -  Psychiatric history.

          -  Pregnant woman or woman need to breast feed or woman with positive chorionic
             gonadotrophin (HCG)

          -  Uncontrolled diabetes or hypertension

          -  Interstitial pneumonia or Active pulmonary fibrosis

          -  Acute bacterial or fungal infection

          -  Oral or intravenous use of steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LuHua Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital of CAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LuHua Wang, MD</last_name>
    <phone>861087788799</phone>
    <email>wlhwq@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Insititute and Hosiptal of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LUHUA WANG, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luhua Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006 Oct 1;24(28):4539-44.</citation>
    <PMID>17008692</PMID>
  </reference>
  <reference>
    <citation>Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992 Dec 3;327(23):1618-24.</citation>
    <PMID>1331787</PMID>
  </reference>
  <reference>
    <citation>Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992 Jun;10(6):890-5.</citation>
    <PMID>1316951</PMID>
  </reference>
  <reference>
    <citation>Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, Payne D, Kostashuk EC, Evans WK, Dixon P, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993 Feb;11(2):336-44.</citation>
    <PMID>8381164</PMID>
  </reference>
  <reference>
    <citation>Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol. 1997 Mar;15(3):893-900.</citation>
    <PMID>9060525</PMID>
  </reference>
  <reference>
    <citation>Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T, Fukuda H, Saijo N. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002 Jul 15;20(14):3054-60.</citation>
    <PMID>12118018</PMID>
  </reference>
  <reference>
    <citation>Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, Yokoyama A, Imamura F, Takeda K, Negoro S, Harada M, Okamoto H, Yamamoto N, Shinkai T, Sakai H, Matsui K, Nakagawa K, Shibata T, Saijo N, Tamura T; Japan Clinical Oncology Group. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol. 2014 Jan;15(1):106-13. doi: 10.1016/S1470-2045(13)70511-4. Epub 2013 Dec 3.</citation>
    <PMID>24309370</PMID>
  </reference>
  <reference>
    <citation>Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999 Aug 12;341(7):476-84.</citation>
    <PMID>10441603</PMID>
  </reference>
  <reference>
    <citation>Carney DN, Mitchell JB, Kinsella TJ. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res. 1983 Jun;43(6):2806-11.</citation>
    <PMID>6303568</PMID>
  </reference>
  <reference>
    <citation>Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999 Jan 28;340(4):265-71.</citation>
    <PMID>9920950</PMID>
  </reference>
  <reference>
    <citation>Movsas B, Moughan J, Komaki R, Choy H, Byhardt R, Langer C, Goldberg M, Graham M, Ettinger D, Johnstone D, Abrams R, Munden R, Starkschall G, Owen J. Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol. 2003 Dec 15;21(24):4553-9. Epub 2003 Nov 3.</citation>
    <PMID>14597743</PMID>
  </reference>
  <reference>
    <citation>Salama JK, Hodgson L, Pang H, Urbanic JJ, Blackstock AW, Schild SE, Crawford J, Bogart JA, Vokes EE; Cancer and Leukemia Group B. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. J Thorac Oncol. 2013 Aug;8(8):1043-9. doi: 10.1097/JTO.0b013e318293d8a4.</citation>
    <PMID>23715301</PMID>
  </reference>
  <reference>
    <citation>Gazula A, Baldini EH, Chen A, Kozono D. Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer. Lung. 2014 Feb;192(1):151-8. doi: 10.1007/s00408-013-9518-9. Epub 2013 Oct 27.</citation>
    <PMID>24162870</PMID>
  </reference>
  <reference>
    <citation>Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27(2):131-46.</citation>
    <PMID>3390344</PMID>
  </reference>
  <reference>
    <citation>Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, Gilligan D, Murray PA, Ruiz de Elvira MC, O'Donnell KM, Gower NH, Harper PG, Hackshaw AK; London Lung Cancer Group. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol. 2006 Aug 20;24(24):3823-30.</citation>
    <PMID>16921033</PMID>
  </reference>
  <reference>
    <citation>Liu HH, Wang X, Dong L, Wu Q, Liao Z, Stevens CW, Guerrero TM, Komaki R, Cox JD, Mohan R. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1268-79.</citation>
    <PMID>15001272</PMID>
  </reference>
  <reference>
    <citation>Chang JY, Dong L, Liu H, Starkschall G, Balter P, Mohan R, Liao Z, Cox JD, Komaki R. Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol. 2008 Feb;3(2):177-86. doi: 10.1097/JTO.0b013e3181622bdd. Review.</citation>
    <PMID>18303441</PMID>
  </reference>
  <reference>
    <citation>Xia B, Chen GY, Cai XW, Zhao JD, Yang HJ, Fan M, Zhao KL, Fu XL. Is involved-field radiotherapy based on CT safe for patients with limited-stage small-cell lung cancer? Radiother Oncol. 2012 Feb;102(2):258-62. doi: 10.1016/j.radonc.2011.10.003. Epub 2011 Nov 5.</citation>
    <PMID>22056536</PMID>
  </reference>
  <reference>
    <citation>Xia B, Hong LZ, Cai XW, Zhu ZF, Liu Q, Zhao KL, Fan M, Mao JF, Yang HJ, Wu KL, Fu XL. Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):517-23. doi: 10.1016/j.ijrobp.2014.09.042. Epub 2014 Dec 3.</citation>
    <PMID>25481679</PMID>
  </reference>
  <reference>
    <citation>Giuliani ME, Lindsay PE, Sun A, Bezjak A, Le LW, Brade A, Cho J, Leighl NB, Shepherd FA, Hope AJ. Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma. Radiother Oncol. 2012 Feb;102(2):263-7. doi: 10.1016/j.radonc.2011.12.009. Epub 2012 Jan 28.</citation>
    <PMID>22285072</PMID>
  </reference>
  <reference>
    <citation>Socha J, Guzowska A, Tyc-Szczepaniak D, Szczęsna A, Kępka L. Hypofractionated conformal radiotherapy in combination with chemotherapy in limited disease small cell lung cancer patients. Pneumonol Alergol Pol. 2014;82(2):105-15. doi: 10.5603/PiAP.2014.0016.</citation>
    <PMID>24615194</PMID>
  </reference>
  <reference>
    <citation>Padda SK, Burt BM, Trakul N, Wakelee HA. Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy. Semin Oncol. 2014 Feb;41(1):40-56. doi: 10.1053/j.seminoncol.2013.12.011. Epub 2013 Dec 12. Review.</citation>
    <PMID>24565580</PMID>
  </reference>
  <reference>
    <citation>Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tomé WA, Chappell RJ, Tolakanahalli R, Mohindra P, Bentzen SM, Cannon GM. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol. 2013 Dec 1;31(34):4343-8. doi: 10.1200/JCO.2013.51.5353. Epub 2013 Oct 21.</citation>
    <PMID>24145340</PMID>
  </reference>
  <reference>
    <citation>Din OS, Harden SV, Hudson E, Mohammed N, Pemberton LS, Lester JF, Biswas D, Magee L, Tufail A, Carruthers R, Sheikh G, Gilligan D, Hatton MQ. Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres. Radiother Oncol. 2013 Oct;109(1):8-12. doi: 10.1016/j.radonc.2013.07.014. Epub 2013 Oct 3.</citation>
    <PMID>24094626</PMID>
  </reference>
  <reference>
    <citation>Osti MF, Agolli L, Valeriani M, Falco T, Bracci S, De Sanctis V, Enrici RM. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):e157-63. doi: 10.1016/j.ijrobp.2012.10.012. Epub 2012 Nov 20.</citation>
    <PMID>23182393</PMID>
  </reference>
  <reference>
    <citation>Amini A, Lin SH, Wei C, Allen P, Cox JD, Komaki R. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiat Oncol. 2012 Mar 15;7:33. doi: 10.1186/1748-717X-7-33.</citation>
    <PMID>22420631</PMID>
  </reference>
  <reference>
    <citation>Kwint M, Uyterlinde W, Nijkamp J, Chen C, de Bois J, Sonke JJ, van den Heuvel M, Knegjens J, van Herk M, Belderbos J. Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy. Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):e223-8. doi: 10.1016/j.ijrobp.2012.03.027. Epub 2012 May 5.</citation>
    <PMID>22560551</PMID>
  </reference>
  <reference>
    <citation>Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, Bradley JD, Barriger RB, Moreno-Jiménez M, Kim TH, Ramella S, Everitt S, Rengan R, Marks LB, De Ruyck K, Warner A, Rodrigues G. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):690-6. doi: 10.1016/j.ijrobp.2013.07.029. Epub 2013 Sep 10. Review.</citation>
    <PMID>24035329</PMID>
  </reference>
  <reference>
    <citation>Stephans KL, Djemil T, Diaconu C, Reddy CA, Xia P, Woody NM, Greskovich J, Makkar V, Videtic GM. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity. Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):197-202. doi: 10.1016/j.ijrobp.2014.05.011. Epub 2014 Jul 8.</citation>
    <PMID>25015204</PMID>
  </reference>
  <reference>
    <citation>Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, Bradley JD, Kim TH, Ramella S, Marks LB, De Petris L, Stitt L, Rodrigues G. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):444-50. doi: 10.1016/j.ijrobp.2012.04.043. Epub 2012 Jun 9. Review.</citation>
    <PMID>22682812</PMID>
  </reference>
  <reference>
    <citation>De Ruysscher D, Bremer RH, Koppe F, Wanders S, van Haren E, Hochstenbag M, Geeraedts W, Pitz C, Simons J, ten Velde G, Dohmen J, Snoep G, Boersma L, Verschueren T, van Baardwijk A, Dehing C, Pijls M, Minken A, Lambin P. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol. 2006 Sep;80(3):307-12. Epub 2006 Sep 1.</citation>
    <PMID>16949169</PMID>
  </reference>
  <reference>
    <citation>Colaco R, Sheikh H, Lorigan P, Blackhall F, Hulse P, Califano R, Ashcroft L, Taylor P, Thatcher N, Faivre-Finn C. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial. Lung Cancer. 2012 Apr;76(1):72-7. doi: 10.1016/j.lungcan.2011.09.015. Epub 2011 Oct 19.</citation>
    <PMID>22014897</PMID>
  </reference>
  <reference>
    <citation>van Loon J, De Ruysscher D, Wanders R, Boersma L, Simons J, Oellers M, Dingemans AM, Hochstenbag M, Bootsma G, Geraedts W, Pitz C, Teule J, Rhami A, Thimister W, Snoep G, Dehing-Oberije C, Lambin P. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):329-36. doi: 10.1016/j.ijrobp.2009.04.075. Epub 2009 Sep 24.</citation>
    <PMID>19782478</PMID>
  </reference>
  <reference>
    <citation>Shirvani SM, Komaki R, Heymach JV, Fossella FV, Chang JY. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e91-7. doi: 10.1016/j.ijrobp.2010.12.072. Epub 2011 Apr 12.</citation>
    <PMID>21489716</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2015</study_first_submitted>
  <study_first_submitted_qc>February 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Luhua Wang</investigator_full_name>
    <investigator_title>Vice President of Cancer hospital of CAMS</investigator_title>
  </responsible_party>
  <keyword>Limited Disease Small Cell Lung Cancer</keyword>
  <keyword>concurrent chemoradiotherapy</keyword>
  <keyword>dose fractionation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

